• 5/31/2008
  • Williamsville, NY
  • staff
  • RTT News (www.rttnews.com)

Saturday, GenVec, Inc. announced the results of a Phase I clinical trial of TNFerade in patients with head and neck cancer, reporting 9 out of 10 evaluable patients in the trial achieved an objective response to treatment.

The company also said that 4 out of the 9 patients achieved complete clinical response by response evaluation criteria in solid tumors or RECIST criteria.